<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137185</url>
  </required_header>
  <id_info>
    <org_study_id>ZGTSH001</org_study_id>
    <nct_id>NCT04137185</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients</brief_title>
  <official_title>Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake Effects For&#xD;
      Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I/II study of rhTSH, To observe the safety and tolerability characteristics of&#xD;
      different doses of rhTSH In Post-thyroidectomized Patients, and to observe the dose-limiting&#xD;
      toxicity (DLT) and maximum tolerated dose (MTD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>up to 7 days</time_frame>
    <description>the maximum tolerathed dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 5 days</time_frame>
    <description>maximum serum thyrotropin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 5 days</time_frame>
    <description>area under curve of serum thyrotropin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Tg</measure>
    <time_frame>up to 7 days</time_frame>
    <description>serum Tg levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radioiodine uptake</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>whole body radioiodine imaging after rhTSH administration and after thyroid hormone withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>classification and degree of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>rhTSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: 0.9mgx1d、0.9mgx2d、1.8mgx1d、1.8mgx2d, intramuscularly (IM) ; Phase 2: patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the Phase 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Thyroid Stimulating Hormone for Injection</intervention_name>
    <description>rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.</description>
    <arm_group_label>rhTSH</arm_group_label>
    <other_name>rhTSH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of differentiated thyroid cancer, including papillary thyroid&#xD;
             cancer (including papillary carcinoma follicular subtype), follicular thyroid cancer,&#xD;
             and Hurthle cell thyroid cancer;&#xD;
&#xD;
          -  Screening ages 18-75 (including 18 Age and 75 years old, male or female;&#xD;
&#xD;
          -  Weight 45kg-80kg (including 45kg and 80kg, limited to the dose escalation test);&#xD;
&#xD;
          -  Complete thyroidectomy or near total resection, and plan to start 131I diagnosis or&#xD;
             ablation Patients&#xD;
&#xD;
          -  Serum TSH ≤ 0.5 mU/L;&#xD;
&#xD;
          -  Women of childbearing age are HCG-negative and must continue contraception until more&#xD;
             than 3 months after the end of the trial;&#xD;
&#xD;
          -  Subjects (including partners) from 2 weeks prior to dosing to the last study drug&#xD;
             There is no pregnancy plan within 3 months after the drug and voluntary effective&#xD;
             contraceptive measures are taken. For specific contraceptive measures, see Appendix 3;&#xD;
&#xD;
          -  Normal ECG. Intermittent atrial premature beats, supraventricular tachycardia (SVT) or&#xD;
             supraventricular block-independent PR interval abnormalities, right bundle branch&#xD;
             block, mild sinus bradycardia (asymptomatic, and no treatment required) Can be&#xD;
             grouped;&#xD;
&#xD;
          -  Low iodine diet before enrollment for more than 4 weeks;&#xD;
&#xD;
          -  Patients are voluntarily enrolled, and written informed consent forms can be used for&#xD;
             treatment and visits as required by the program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not eligible for THST withdrawal due to pituitary disease or other&#xD;
             diseases;&#xD;
&#xD;
          -  Patients not eligible for 131I diagnosis or treatment;&#xD;
&#xD;
          -  Any significant clinical and laboratory abnormalities (eg, severe cardiopulmonary&#xD;
             disease, hepatic insufficiency, renal function) Incomplete, congestive heart failure,&#xD;
             advanced lung disease or advanced cardiovascular and cerebrovascular disease, active&#xD;
             infection);&#xD;
&#xD;
          -  Hypertensive patients who cannot be reduced to the following range due to medical&#xD;
             treatment (systolic blood pressure &lt;140 mmHg, diastolic blood pressure &lt;90 mmHg);&#xD;
&#xD;
          -  Patients who have used any water-soluble radiographic contrast agent intravenously&#xD;
             within 4 weeks before administration;&#xD;
&#xD;
          -  Patients who underwent intrathecal iodine angiography or gallbladder iodine imaging&#xD;
             within 3 months prior to administration;&#xD;
&#xD;
          -  taken/eaten within 4 weeks prior to administration Drugs/foods that affect iodine&#xD;
             uptake or metabolism, such as multivitamins, glucocorticoids, diuretics, lithium,&#xD;
             thiouracil, tazobactam, algae, iodine (except thyroid hormone replacement therapy);&#xD;
&#xD;
          -  before administration Stroke, unstable angina (CCS class II or higher), atrial&#xD;
             fibrillation or medication (within beta blocker or digoxin) within 6 months Patients&#xD;
             with a history of arrhythmia;&#xD;
&#xD;
          -  pregnant or lactating women;&#xD;
&#xD;
          -  a history of drug use and/or alcohol abuse within 3 months prior to dosing;&#xD;
&#xD;
          -  patients who are allergic to rhTSH and its excipients;&#xD;
&#xD;
          -  patients with positive infection-related tests : Includes hepatitis C and AIDS;&#xD;
&#xD;
          -  Participated in any drug or medical device clinical trial within 1 month prior to the&#xD;
             trial;&#xD;
&#xD;
          -  Those who were unable to participate in the trial as judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Yan Song, MD</last_name>
    <phone>13671116837</phone>
    <email>linys@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Yan Song, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

